SHARE

OFFER: Technology for haemolysis detection

15th mai 2020

Hemcheck offers two free solutions for point-of-care testing

Hemcheck is offering two solutions to increase speed of blood testing in the clinical setting during the COVID-19 pandemic.

Both solutions use their unique concept, HELGE™ which detects haemolysis in blood samples in vacuum tubes and blood gas syringes during blood sampling at the point of care.

  1. Informed and timely clinical decisions:

Given the critical situation with the outbreak and rapid spread of COVID-19 in society, HELGE™ could improve the flow of blood samples in clinical laboratories, emergency departments, infection clinics, intensive care units and ambulatory/mobile units. This, in turn, may decrease  turnaround times and overcrowding as well as reduce the workload of healthcare staff.

  1. Testing in different settings:

The company’s second offer focuses on haemolysis detection in blood samples for SARS-CoV-2 antibody testing in different settings, such as mobile clinics or nursing homes.  HELGETM makes it possible to collect and test for haemolysis outside of a hospital setting, reducing the need for patients to travel during the pandemic.

HELGE™ consists of three parts; a disposable test for vacuum tubes (v-Test), a disposable test for blood gas syringes (s-Test) and a joint reader for reliable answers in 5-10 seconds. About 100 ul of the whole blood sample is inserted into the disposable test during blood collection. The single-use test separates plasma/serum in about one second. The test is then placed on the mobile reader (driven by a rechargeable battery) for measurement to define if the blood is haemolysed or not, given a predefined (adjustable) cut-off value, presented as a binary result through a red or green led indicator.

More information about the concept visit: https://hemcheck.com

Conditions of the offer:

  • The offer is valid for three months
  • The offer is will be subject to a separate and mutual agreement, with no ongoing obligation
  • Hemcheck should be able to carry out training of healthcare and laboratory staff using the equipment via web link.
  • Hemcheck should have the opportunity to evaluate the usage, for example through a simple user survey and/or follow up the effect on the heamolysis rate.
  • The using department should have an interest in evaluating the product for a possible implementation in routine work after the trial period.
  • Hemcheck cannot support too many hospitals at the same time due to capacity constraints so the offer is based on a first come, first served principle.

Hemcheck remains the right to decline requests that they are not able to accept and serve due to capacity constraints.

For more information please contact
Peter Andersson

| | Hemcheck
Contact

ASK: Research contributors needed for CON-VICE study

ASK: Research contributors needed for CON-VICE study

University of Luxembourg needs European researchers to get in touch

Find out more

OFFER: Funding available for COVID-19 research

OFFER: Funding available for COVID-19 research

Fondation Air Liquide are looking to fund European projects

Find out more

ASK: Supporting the immunocompromised

ASK: Supporting the immunocompromised

Partners sought to advance neutralising antibody

Find out more